Company Overview of Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical tri...
167 Sidney Street
Cambridge, MA 02139
Founded in 1989
Key Executives for Idera Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $600.0K
Chief Financial Officer, Senior Vice President of Operations, Treasurer and Assistant Secretary
Total Annual Compensation: $347.5K
President of Research and Director
Total Annual Compensation: $588.1K
Senior Vice President, General Counsel and Secretary
Total Annual Compensation: $371.0K
Senior Vice President of Business Development & Strategic Planning
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2016.
Idera Pharmaceuticals, Inc. Key Developments
Idera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2017
May 4 17
Idera Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported alliance revenue of $378,000 compared to $294,000 a year ago. Loss from operations was $15,188,000 compared to $12,918,000 a year ago. Net loss was $15,057,000 compared to $12,823,000 a year ago. Basic and diluted net loss per common share applicable to common stockholders was $0.10 compared to $0.11 a year ago.
Idera Pharmaceuticals, Inc. Announces Executive Changes
Apr 18 17
Idera Pharmaceuticals, Inc. announced that Sudhir Agrawal, D. Phil, the company's President of Research and member of the company's Board of Directors, plans to retire on May 31, 2017. However, Dr. Agrawal will continue to contribute to the company as a scientific advisor. Jonathan Yingling, Ph.D., Idera's Senior Vice President and Head of Early Development will assume interim leadership of the company's research organization.
Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma
Apr 11 17
Idera Pharmaceuticals, Inc. announced successful completion of the phase 1 portion of the ongoing Phase 1/2 clinical trial of intratumoral IMO-2125. Intratumoral IMO-2125 is an agonist of TLR9, in combination with ipilimumab for the treatment of anti-PD-1 refractory metastatic melanoma. Enrollment has begun for the Phase 2 portion of the trial with the 8mg dose of intratumoral IMO-2125. The Phase 1 dose escalation of IMO-2125 in combination with pembrolizumab is ongoing. The Phase 2 portion of the trial utilizes a Simon two-stage design to evaluate the objective response rate of IMO-2125 in combination with ipilimumab, compared to historical data for ipilimumab alone in the anti-PD-1 refractory metastatic melanoma population. The ipilimumab arm of IMO-2125-204 has already met the pre-specified futility assessment to advance immediately into the second stage of the Phase 2 portion of the trial given that 2 patients treated at the Phase 2 dose experienced confirmed responses, including one complete response (CR). All dose levels of IMO-2125 in the Phase 1 portion of the trial have been well tolerated; however the 8 mg dose level has been selected for the Phase 2 portion of the trial based on its safety, clinical efficacy, and data from multiple translational immune parameters supporting the mechanism. Phase 2 will evaluate twenty-one patients dosed at 8mg, of which 9 are already enrolled. The MD Anderson Cancer Center will continue to lead the trial and will be joined by additional centers. In addition to potential interim updates, the company expects to have overall response rate (ORR) data available in the first quarter of 2018. Additionally, the company has begun and will continue to engage in discussions with regulatory authorities regarding the path to registration for IMO-2125 in combination with ipilimumab in PD-1 refractory metastatic melanoma patients. The Phase 1 clinical trial of intratumoral IMO-2125 in combination with pembrolizumab in PD-1 refractory melanoma patients is enrolling as expected, and patient enrollment in a phase 1 trial of intratumoral IMO-2125 monotherapy in multiple tumor types has been activated and the first patient is expected to enroll early this quarter.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|